Effect of alprostadil on serum H-FABP and MMP-9 levels in patients with acute coronary syndrome

Abstract

Objective To study the effect of alprostadil on serum heart-type fatty acid binding protein（ H-FABP）and matrix metalloproteinase-9（ MMP-9 ）in patients with acute coronary syndrome. Methods Ninety-eight patients with acute coronary syndrome were randomly divided into two groups, the control group（49 cases）and the observation group（49 cases）. The patients in the control group were treated by the conventional treatment,while the patients in the observation group were treated by the conventional treatment plus alprostadil. They were treated for 14 days. Serum H-FABP and MMP-9 levels were detected before and after treatment. The incidence of primary endpoint were observed after 30 d, 3 months and 6 months discharged from hospital. Results In the control group,after 30 d,3 months, 6 months discharged from hospital,the primary endpoint occurred cases was 5,10,18. In the observation group,after 30 d,3 months,6 months discharged from hospital,the primary endpoint occurred cases was 1,5,8. There were significant differences（P ﹤0. 01）. After treatment,the serum H-FABP and MMP-9 evels were significantly lower（P﹤0. 01）,compared with the control group,the levels in observation group decreased more significantly after treatment（ P﹤0. 05 ）. Conclusions Alprostadil can decrease the serum H-FABP and MMP-9 levels in patients with acute coronary syndrome. Key words: Acute coronary syndrome; Alprostadil; Heart-type fatty acid binding protein; Matrix metalloproteinase-9